RUA Life Sciences (LSE:RUA) Selling and Marketing Expense: £0.00 Mil (TTM As of Mar. 2025)


LSE:RUA RUA Life Sciences PLC LSE:RUA
58 GF Score
Price £0.19
GF Value £0.16
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is RUA Life Sciences Selling and Marketing Expense?

RUA Life Sciences LSE:RUA 58 Selling and Marketing Expense is £0.00 Mil as of Mar. 2025. GuruFocus rates LSE:RUA with a GF Score™ of 58/100 and a GF Value™ of £0.16 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. RUA Life Sciences's Selling and Marketing Expense for the six months ended in Mar. 2025 was £0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 was £0.00 Mil.

RUA Life Sciences Selling and Marketing Expense Related Terms

RUA Life Sciences Selling and Marketing Expense Historical Data

* Premium members only.

The historical data trend for RUA Life Sciences's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RUA Life Sciences Selling and Marketing Expense Chart

RUA Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.01 0.02 0.01

RUA Life Sciences Semi-Annual Data
Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:RUA
58GF Score
RUA Life Sciences PLC LSE:RUA
Selling and Marketing Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RUA Life Sciences Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling and Marketing Expense of £0.00 Mil mean?
RUA Life Sciences (LSE:RUA) has a Selling and Marketing Expense of £0.00 Mil as of Mar. 2025. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on RUA Life Sciences and its competitors.
Is RUA Life Sciences' Selling and Marketing Expense too high?
RUA Life Sciences' current Selling and Marketing Expense is £0.00 Mil. Overall, RUA Life Sciences has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Selling and Marketing Expense compare to ABT and SYK?
RUA Life Sciences' Selling and Marketing Expense of £0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling and Marketing Expense for a Medical Devices & Instruments company?
A good Selling and Marketing Expense depends on the Medical Devices & Instruments industry context. However, Selling and Marketing Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling and Marketing Expense mean?
A high Selling and Marketing Expense can signal that a stock is expensive relative to its fundamentals. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on RUA Life Sciences and its competitors. RUA Life Sciences's current Selling and Marketing Expense is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (LSE:RUA) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.16, compared to a current price of £0.19 — trading 18.8% above its estimated fair value. The current Selling and Marketing Expense is £0.00 Mil. RUA Life Sciences' overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling and Marketing Expense calculated?
Selling and Marketing Expense is calculated from a company's financial statements. For RUA Life Sciences (LSE:RUA), the current Selling and Marketing Expense is £0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RUA Life Sciences (LSE:RUA) Overvalued in 2026?

Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued. The current stock price of £0.19 is trading 18.8% above its estimated GF Value™ of £0.16. GuruFocus considers RUA Life Sciences to be Modestly Overvalued.

Key valuation signals for LSE:RUA:

  • Selling and Marketing Expense: £0.00 Mil
  • GF Value™: £0.16 vs. price of £0.19 (18.8% above fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the LSE:RUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RUA Life Sciences Business Description

Other Exchanges AOHA:Germany
Address 2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
58GF Score

Get the complete analysis for LSE:RUA

Selling and Marketing Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.19
Price
£0.16
GF Value